Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib with CHOP in ALK(+) Systemic Anaplastic Large Cell Lymphoma
NCT02487316Phase 4Withdrawn
- Start
- Jul 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of crizotinib in Anaplastic Large Cell Lymphoma (ALCL). Planned start Jul 2015; status: withdrawn.
02
Drugs
crizotinib
03
Conditions
Anaplastic Large Cell Lymphoma (ALCL)
Beyond the preview
Go deeper on NCT02487316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487316.